Article from All Aboard: "The advantage to peptide-based vaccines is that they can be pushed through development very quickly, while other kinds of vaccines often take months — or even years — to complete.

“You could get into a phase one safety trial within weeks,” De Groot says. “Four weeks at the shortest,” from start to finish.

The disadvantage, De Groot says, is peptide vaccine cannot be easily mass-produced, and they don’t protect against infection.

“It fortifies your immune system so that you don’t get as sick when you’re infected,” she says. “I think it would buy us time.”

Time for other scientists to develop and produce vaccines that can be distributed more widely. Until then, De Groot says, a peptide vaccine could be used to protect health care workers or others at high risk, and it could help slow the spread of the virus."